Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Efficacy and safety of tulisokibart, prednisolone and placebo in adults with active non‑infectious uveitis

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults with active noninfectious intermediate, posterior, or panuveitis, a rare eye condition that causes inflammation in the middle and back parts of the eye and can lead to blurry vision or loss of sight. Participants will receive a subcutaneous injection, which means the medication is placed just under the skin, of the experimental drug tulisokibart or a matching placebo. All participants may also continue taking oral prednisone, a steroid that helps reduce inflammation, as part of their usual care.

The purpose of the study is to determine whether tulisokibart can keep the eye disease under control better than the placebo by measuring the time it takes for the disease to worsen, known as treatment failure, after the first six weeks and up to about a year later. After a screening visit, participants will be given the assigned injection at regular intervals and will attend clinic visits where doctors will check the health of the eye, note any side effects, and test visual acuity (the sharpness of vision). The study continues for several months, with safety checks throughout, and ends when the final follow‑up visit is completed.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit and Initial Assessments

    After joining the study, you will attend a baseline visit where a doctor will examine your eyes, record your medical history, and perform any required laboratory tests.

    These assessments establish the condition of your non‑infectious uveitis before any study medication is given.

  2. Step 2

    Randomization to Study Medication

    Based on the study design, you will be randomly assigned to receive either tulisokibart or a placebo.

    Randomization ensures that the assignment is unbiased and that the study results are reliable.

  3. Step 3

    First Subcutaneous Injection

    You will receive a subcutaneous injection (injection under the skin) of the assigned study medication using a pre‑filled injector.

    The data lists the dose as 0 mg, indicating that the exact amount will be defined by the study protocol and administered by the clinical staff.

  4. Step 4

    Background Oral Prednisone

    In addition to the study injection, you may be instructed to take oral prednisolone as background therapy.

    The provided information records the dose as 0 mg, meaning the specific dosage will be determined by the trial investigators.

  5. Step 5

    Regular Follow‑Up Visits and Additional Injections

    You will return to the clinic at scheduled intervals for up to week 50 of the trial.

    During each visit you will receive another subcutaneous injection of the same study medication, undergo eye examinations, and report any side effects.

    The frequency of visits follows the study schedule, which continues until the final assessment at week 50.

  6. Step 6

    Evaluation for Treatment Failure

    Starting at week 6 and continuing through week 50, the study team will assess whether the disease shows signs of treatment failure.

    Treatment failure is defined by specific clinical criteria outlined in the trial protocol.

  7. Step 7

    Mid‑Study Assessment at Week 26

    At week 26, you will have a detailed eye examination to evaluate changes in vitreous haze and visual acuity.

    These measurements help determine how well the study medication is working compared with the placebo.

  8. Step 8

    Final Study Visit and Completion

    At the end of the study period (week 50), you will undergo a final eye examination and safety assessment.

    After this visit, your participation in the trial is considered complete.

Who can join the trial?

4 criteria

  • Have active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (these are types of eye inflammation that are not caused by infection) in at least one eye when screened and before starting the study medication.
  • Be able to take any allowed immunosuppressive medicines or corticosteroids (anti‑inflammatory steroids) at the same dose for a set period of time before the study begins.
  • Fall within the age range that the study includes, which covers both children and adults.
  • Be either male or female, as both sexes are eligible to participate.

Who cannot join the trial?

24 criteria

  • Having only front‑eye inflammation called anterior uveitis without involvement of the deeper parts of the eye.
  • Planning to have eye surgery during the period when the study medication is being given.
  • Having had any laser eye procedures (such as refractive laser surgery, laser treatment of the macula, retinal laser, or a special laser capsulotomy) within 30 days before the first study visit.
  • Having any other eye surgery within the past 3 months, except purely cosmetic surgery that will not affect vision.
  • Having had a major operation (one that required general anesthesia) within the past 3 months, or planning such an operation during the study.
  • Being unable to use or respond to mydriatic eye drops (drops that widen the pupil) enough to allow the doctor to see the back of the eye clearly.
  • Having any condition that makes it impossible to examine both eyes throughout the study.
  • Having another immune‑related inflammatory disease that is not well controlled and might need medicines that are not allowed in the study.
  • Having an organ transplant and needing ongoing medicines that suppress the immune system.
  • Having a history of cancer (except fully treated skin cancers or early‑stage cervical cancer) and being cancer‑free for less than 5 years before the study starts.
  • Having test results that suggest a possible cancer that cannot be ruled out with further examinations.
  • Having swelling of the central part of the retina (macular edema) as the only sign of the eye disease being studied.
  • Having any active infection at the time of screening.
  • Having shown intolerance to, or not responded adequately to, high‑dose oral steroids (equivalent to prednisone 1 mg per kilogram of body weight per day or at least 60 mg per day) in the three months before screening.
  • Having had problems related to a steroid implant placed in the eye.
  • Being allergic or overly sensitive to the study drug tulisokibart or any of its inactive ingredients.
  • Having an allergy or intolerance to the steroid medicines prednisone or prednisolone.
  • Having a condition called presumed ocular histoplasmosis syndrome, a fungal‑related eye disease.
  • Having a specific retinal disease called serpiginous choroidopathy or severe diabetic eye disease (proliferative or severe non‑proliferative retinopathy) with significant macular swelling.
  • Having advanced diabetic eye disease (proliferative or severe non‑proliferative retinopathy) with significant macular swelling.
  • Having “wet” age‑related macular degeneration, a condition where abnormal blood vessels grow under the retina.
  • Having active inflammation of the white outer coating of the eye (scleritis) within the past 6 months.
  • Having a visual acuity score of less than 20 letters on the standard eye chart (ETDRS) in either eye at the start of the study.
  • Having clouding of the cornea or lens that blocks the view of the back of the eye or is likely to require cataract surgery during the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • tulisokibart

    is an experimental medication being tested in this study. It is given as a subcutaneous injection using a pre‑filled injector. The drug is being evaluated to see if it can help control inflammation in the eye for people with active non‑infectious intermediate, posterior, or panuveitis. Researchers will compare how well it works to a placebo and will watch for any side effects.

  • prednisone

    is a steroid medication that is taken by mouth. In this trial, it is used as background therapy, meaning all participants continue their usual prednisone treatment while the study tests the new drug. Prednisone helps reduce eye inflammation and is part of standard care for uveitis, allowing the study to assess whether the new medication adds any extra benefit.

What is already known about the treatment

  • tulisokibart

    This medication is given as a solution for injection in a pre‑filled injector and is administered under the skin (subcutaneous injection). It is an investigational drug currently in Phase 2b clinical trials and has not yet been approved for general medical use. The drug is being tested for the treatment of noninfectious intermediate, posterior, or panuveitis, a rare inflammatory eye condition. It works by blocking specific molecules that trigger inflammation, placing it in the class of experimental anti‑inflammatory agents.

  • prednisolone

    Prednisolone is taken by mouth in tablet form. It is an approved corticosteroid that has been used for many decades to treat a wide range of inflammatory and autoimmune disorders. In this study it serves as background therapy for inflammatory eye disease. The drug binds to glucocorticoid receptors, which then reduces the activity of immune cells and lowers inflammation, classifying it as a glucocorticoid steroid.

Investigated diseases

Noninfectious intermediate, posterior, or panuveitis (NIIPPU) - This disease is an inflammation of the eye that is not caused by infection and can involve the middle layer (intermediate), the back part (posterior), or all layers (panuveitis). It often begins with subtle symptoms such as blurred vision, floaters, or light sensitivity. Over time the inflammation may spread from one part of the eye to another, leading to more extensive swelling. Persistent or recurrent inflammation can gradually affect the structures of the eye, including the retina and optic nerve. If the process continues, it can cause secondary changes such as cataract formation or increased eye pressure.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IITrial ID2025-524059-30-00Protocol codeMK-7240-019Estimated enrolment54 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.